Cart
sales@molnova.com
Apitegromab
CAS No. 2278276-46-1
Apitegromab( —— )
Catalog No. M36899 CAS No. 2278276-46-1
Apitegromab (SRK-015) is a new myostatin inhibitor, an antibody targeting myostatin precursor, which can be used to study neuromuscular diseases including spinal muscular atrophy.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 471 | In Stock |
|
| 10MG | 755 | In Stock |
|
| 25MG | 1121 | In Stock |
|
| 50MG | 1469 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameApitegromab
-
NoteResearch use only, not for human use.
-
Brief DescriptionApitegromab (SRK-015) is a new myostatin inhibitor, an antibody targeting myostatin precursor, which can be used to study neuromuscular diseases including spinal muscular atrophy.
-
DescriptionApitegromab (SRK-015) is an anti-promyostatin monoclonal antibody. Apitegromab can be used for the research of neuromuscular disease including spinal muscular atrophy.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayEndocrinology/Hormones
-
TargetOpioid Receptor
-
RecptorOpioid Receptor
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2278276-46-1
-
Formula Weight
-
Molecular Formula——
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
-
Cannabidiol
Cannabidiol is GPR55 and weak CB1 antagonist (IC50s: 0.445 and 3.35 μM) CB2 receptor inverse agonist and inhibitor of anandamide uptake (IC50: 27.5 μM). It also a weak agonist at VR1 vanilloid receptors (EC50: 3.5 μM).
-
PL 017
Selective μ opioid receptor agonist (IC50 values are 5.5 and > 10000 nM for inhibition of 125I-FK 33,824 and 125I-DADLE binding to μ and δ sites respectively). Produces naloxone-reversible analgesia, catalepsy and hyperthermia following central administration in rats in vivo.
-
UFP-101
Potent, selective and competitive silent antagonist for the NOP opioid receptor. Binds to NOP with high affinity (pKi = 10.24) and displays > 3000-fold selectivity over δ, μ and κ opioid receptors. Antinociceptive and opposes the action of nociceptin in vivo.
